RxDoctor Payments Data

Bianca Kizy, MD

Ophthalmology · Royal Oak, MINPI 1548655152

Payments from drug & device makers

$1,355in general payments, 2019–2025

Across 62 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$246
  • Bausch & Lomb Americas Inc.$142
  • Ocular Therapeutix, Inc.$141
  • Tarsus Pharmaceuticals, Inc.$110
  • Glaukos Corporation$104
  • AbbVie$99
  • plus $515 from 13 others

What the payments were for

  • Food & beverage$1,355100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,355 in reported general payments places this provider in the 50th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$117,837
Medicare patients
291
Services billed
1,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine23$36,807
XiidraLifitegrast15$16,542
Prednisolone Acetate310$16,463
LumiganBimatoprost35$16,184
CombiganBrimonidine Tartrate/Timolol26$12,998
MieboPerfluorohexyloctane/Pf16$11,802
Latanoprost551$9,722
SimbrinzaBrinzolamide/Brimonidine Tart20$8,258
Ketorolac Tromethamine315$4,914
MoxifloxacinMoxifloxacin Hcl219$3,898
Brimonidine Tartrate177$3,432
ErythromycinErythromycin Base276$3,291
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat126$3,131
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$2,795
Fluorometholone21$1,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$99$65,98984 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$142$28,34431 claims
AlconSimbrinza$246$8,25820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Royal Oak

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →